Multiplexed COVID-19 antibody quantification from human sera using label-free nanoplasmonic biosensors.
Biomed Opt Express
; 13(4): 2130-2143, 2022 Apr 01.
Article
in English
| MEDLINE | ID: covidwho-1770630
ABSTRACT
Serological assays that can reveal immune status against COVID-19 play a critical role in informing individual and public healthcare decisions. Currently, antibody tests are performed in central clinical laboratories, limiting broad access to diverse populations. Here we report a multiplexed and label-free nanoplasmonic biosensor that can be deployed for point-of-care antibody profiling. Our optical imaging-based approach can simultaneously quantify antigen-specific antibody response against SARS-CoV-2 spike and nucleocapsid proteins from 50 µL of human sera. To enhance the dynamic range, we employed multivariate data processing and multi-color imaging and achieved a quantification range of 0.1-100 µg/mL. We measured sera from a COVID-19 acute and convalescent (N = 24) patient cohort and negative controls (N = 5) and showed highly sensitive and specific past-infection diagnosis. Our results were benchmarked against an electrochemiluminescence assay and showed good concordance (Râ¼0.87). Our integrated nanoplasmonic biosensor has the potential to be used in epidemiological sero-profiling and vaccine studies.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Cohort study
/
Diagnostic study
/
Observational study
/
Prognostic study
Topics:
Vaccines
Language:
English
Journal:
Biomed Opt Express
Year:
2022
Document Type:
Article
Affiliation country:
BOE.454919
Similar
MEDLINE
...
LILACS
LIS